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Abstract DNA copy-number gains of chromosomes 8q,
13q, and 20q are frequently observed in gastric cancers.
Moreover gain of chromosome 20q has been associated with
lymph node metastasis. The aim of this study was to
correlate DNA copy-number changes of individual genes
on chromosomes 8q, 13q, and 20q in gastric adenocarcino-
mas to clinicopathological data. DNA isolated from 63
formalin-fixed and paraffin-embedded gastric adenocarcino-
ma tissue samples was analyzed by whole-genome micro-
array comparative genomic hybridization and by multiplex
ligation-dependent probe amplification (MLPA), targeting
58 individual genes on chromosomes 8, 13, and 20. Using
array comparative genomic hybridization, gains on 8q, 13q,
and 20q were observed in 49 (77.8%), 25 (39.7%), and 49
(77.8%) gastric adenocarcinomas, respectively. Gain of
chromosome 20q was significantly correlated with lymph
node metastases (p=0.05) and histological type (p=0.02).
MLPA revealed several genes to be frequently gained in
DNA copy number. The oncogene c-myc on 8q was gained
in 73% of the cancers, while FOXO1A and ATP7B on 13q
were both gained in 28.6% of the cases. Multiple genes on
chromosome 20q showed gains in more than 60% of the
cancers. DNA copy-number gains of TNFRSF6B (20q13.3)
and ZNF217 (20q13.2) were significantly associated with
lymph node metastasis (p=0.02) and histological type (p=
0.02), respectively. In summary, gains of chromosomes 8q,
13q, and 20q in gastric adenocarcinomas harbor DNA
copy-number gains of known and putative oncogenes.
ZNF217 and TNFRSF6B are associated with important
clinicopathological variables, including lymph node status.
Keywords DNA copy-number . Gastric cancer .
Lymph node status .MLPA
Introduction
Gastric cancer is a major health problem and ranks second
as a cause of cancer death worldwide [1]. The only possible
curative treatment is complete surgical resection. One of the
hallmarks of solid cancers, including gastric cancer, is
chromosomal instability leading to gains and losses of parts
of, or even whole chromosomes [2]. The mechanisms
underlying this instability phenotype in gastric cancers are
still poorly understood. Patterns of DNA copy-number
aberrations can be analyzed at high resolution by array
comparative genomic hybridization (CGH). Gains of
chromosomes 3q, 7p, 7q, 8q, 13q, 17q, and 20q and losses
of chromosomes 4q, 5q, 6q, 9p, 17p, and 18q have been
consistently described in gastric cancer studies using CGH
or array CGH analysis [3–11]. In addition, gains of
chromosomes 7q, 8q, 9q, 11q, 13q, and 20q and losses of
chromosomes 4p, 5q, 6, 9p, 17p, and 18q can already be
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detected in gastric cancer precursor lesions with direct
malignant potential, indicating these as early events in the
pathogenesis of gastric cancer [12–16]. Results from array
CGH studies have shown that patterns of chromosomal
aberrations can be correlated with clinicopathological
variables. In previous studies, we have shown different
patterns of chromosomal instability to correlate with
lymph node status and with age of onset of the disease
[17, 18].
DNA copy-number gains of chromosomes 8, 13, and 20
have been described to play an important role in colorectal
adenoma to carcinoma progression [19, 20]. Also in gastric
adenomas and adenocarcinomas, gains of these chromo-
somes have frequently been detected, indicating the impor-
tance of genetic events on these chromosomes for gastric
cancer pathogenesis. Moreover, gain of chromosome 20q has
been described to correlate with lymph node metastasis in
gastric cancer and poor clinical outcome in colorectal cancer
[3, 21, 22]. The most widely used array CGH platforms, so
far, use spotted bacterial artificial chromosomes (BACs),
which means that the probe sequences on the arrays cover up
to 1 kb of DNA. This approach is very suitable for detecting
patterns of DNA copy-number changes but has limitations in
pinpointing individual genes whose normal function is
disrupted due to these chromosomal aberrations. Multiplex
ligation-dependent probe amplification (MLPA) [23] allows
to determine in a single experiment DNA copy-number
ratios of up to 40 individual genes and can be used to zoom
in on chromosomal areas that show aberrations with array
CGH [24, 25]. The aim of the present study is a detailed
analysis of DNA copy-number changes of individual genes
within gained areas on chromosomes 8, 13, and 20 in gastric
adenocarcinomas and to correlate gene specific alterations to
clinicopathological data.
Materials and methods
Materials and DNA isolation
DNA of 63 formalin-fixed and paraffin-embedded (FFPE)
gastric adenocarcinomas of which 53 were obtained from
Leeds (Leeds University Hospital, UK) and 10 were
obtained from the Dutch D1/D2 trial [26], was isolated as
previously described [17] using a commercial available
DNA isolation kit (QIAmp DNA microkit, Qiagen, Hilden,
Germany). Briefly, areas of at least 70% tumor cells were
demarcated on a 4-µm haematoxylin- and eosin-stained
tissue section. Adjacent serial sections of 10µm were cut,
and after deparaffination, the tumor tissue was macro-
dissected using a needle. After an overnight incubation with
sodium thiocyanate (1 M) at 37°C, followed by proteinase
K treatment, DNAwas extracted. DNA concentrations were
measured on a Nanodrop ND-1000 spectrophotometer
(Isogen, IJsselstein, The Netherlands), and DNA quality
was assessed by isothermal amplification as previously
described [27]. Only DNA of excellent, good, and
intermediate quality was used for further analysis.
Table 1 An overview of DNA copy number gains of chromosomes 8q, 13q and 20q detected by array CGH in 63 gastric adenocarcinomas, and
the correlation to lymph node status and histological type of the tumor
Chromosome Status All cases Lymph node status P value Histological type P value
LN0 LN1 Intestinal Diffuse Mixed
n=63 n=22 n=41 n=38 n=17 n=8
8q Gain 49 (77.8%) 18 (81.8%) 31 (75.6%) 0.57 29 (76.3%) 13 (76.5%) 7 (87.5%) 0.78
No gain 14 (22.2%) 4 (18.2%) 10 (24.4%) 9 (23.7%) 4 (23.5%) 1 (12.5%)
13q Gain 25 (39.7%) 10 (45.5%) 15 (36.6%) 0.49 19 (50.0%) 4 (23.5%) 2 (25.0%) 0.12
No gain 38 (60.3%) 12 (54.5%) 26 (63.4%) 19 (50.0%) 13 (76.5%) 6 (75.0%)
20q Gain 49 (77.8%) 14 (63.6%) 35 (85.4%) 0.048 33 (86.8%) 9 (52.9%) 7 (87.5%) 0.016
No gain 14 (22.2%) 8 (36.4%) 6 (14.6%) 5 (13.2%) 8 (47.1%) 1 (12.5%)
8q+13q+20q Gain 17 (27.0%) 6 (27.2%) 11 (26.8%) 0.97 13 (34.2%) 2 (11.8%) 2 (25.0%) 0.22
No gain 46 (73.0%) 16 (72.7%) 30 (73.2) 25 (65.8%) 15 (88.2%) 6 (75.0%)
8q+13q Gain 4 (6.3%) 3 (13.6%) 1 (2.4%) 0.082 2 (5.3%) 2 (11.8%) 0 (0.0%) 0.48
No gain 59 (93.7%) 19 (86.4%) 40 (97.6%) 36 (94.7%) 15 (88.2%) 8 (100.0%)
8q+20q Gain 24 (38.1%) 8 (36.4%) 16 (39.0%) 0.84 14 (36.8%) 6 (35.3%) 4 (50.0%) 0.76
No gain 39 (61.9%) 14 (63.6%) 25 (61.0%) 24 (63.2%) 11 (64.7%) 4 (50.0%)
13q+20q Gain 3 (4.8%) 0 (0.0%) 3 (7.3%) 0.19 3 (7.9%) 0 (0.0%) 0 (0.0%) 0.36
No gain 60 (95.2%) 22 (100.0%) 38 (92.7%) 35 (92.1%) 17 (100.0%) 8 (100.0%)
Gain of 20q is significantly correlated to lymph node status and histological tumor type (in bold)
LN0 lymph node-negative, LN1 lymph node-positive
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DNA labeling and array CGH)
DNA labeling and array CGH were essentially performed
as previously described [17, 28]. In short, tumor and
normal DNA were differentially labeled using random
priming (Bioprime DNA Labeling System; Invitrogen,
Breda, The Netherlands) and hybridized on a BAC array
containing approximately 5,000 clones printed in triplicate,
consisting of the Sanger BAC clone set with an average
resolution along the whole genome of 1.0 Mb (http://www.
ensembl.org/Homo_sapiens/cytoview), the OncoBac set
(http://informa.bio.caltech.edu/Bac_onc.html), containing
approximately 600 clones corresponding to 200 cancer-
related genes, and selected clones of interest obtained from
the Children_s Hospital Oakland Research Institute
(CHORI) to fill any gaps larger than 1 Mb on chromosome
6 and to have full-coverage contigs of regions on
chromosomes 8, 11, 13, and 20. All clones were printed
on Codelink™ slides (Amersham BioSciences, Roosendaal,
The Netherlands) at a concentration of 1 μg/μl in 150-mM
sodium phosphate, pH 8.5, using an OmniGrid 100 micro-
arrayer (Genomic Solutions, Ann Arbor, MI, USA) equipped
with SMP3 pins (TeleChem International, Sunnyvale, CA,
USA), and processed according to the manufacturer_s
protocol.
After hybridization, images of the arrays were acquired
by scanning (Microaray scanner G2505B; Agilent technol-
ogies, Palo Alto, USA), and spot analysis and quality
control were automatically performed using BlueFuse 3.4
software (BlueGnome, Cambridge, UK). When the Blue-
Table 2 Overview of patient and tumor characteristics of the 63 gastric adenocarcinomas analyzed in the study
Tumor ID Gender Age Histological type T status N status Tumor ID Gender Age Histological type T status N status
1 Female 78 Intestinal T3 N1 33 Male 75 Intestinal T2 N3
2 Female 81 Diffuse T3 N1 34 Male 61 Intestinal T3 N3
3 Female 54 Intestinal T2 N0 35 Female 82 Diffuse T3 N1
4 Male 73 Intestinal T3 N1 36 Male 74 Mixed T2 N1
5 Male 81 Mixed T2 N2 37 Female 87 Diffuse T3 N2
6 Male 58 Intestinal T2 N1 38 Female 78 Intestinal T1 N0
7 Female 72 Intestinal T2 N0 39 Male 78 Diffuse T2 N0
8 Male 86 Intestinal T2 N2 40 Female 84 Intestinal T2 N0
9 male 71 Intestinal T3 N0 41 Male 85 Diffuse T3 N2
10 Female 75 Intestinal T4 N1 42 Male 62 Diffuse T3 N3
11 Female 75 Intestinal T3 N2 43 Male 68 Intestinal T3 N1
12 Male 64 Mixed T3 N1 44 Male 58 Intestinal T4 N1
13 Male 81 Intestinal T2 N2 45 Male 61 Diffuse T3 N1
14 Male 63 Intestinal T2 N0 46 Female 58 Intestinal T3 N1
15 Male 63 Intestinal T3 N1 47 Male 81 Intestinal T3 N1
16 Male 68 Mixed T2 N0 48 Female 65 Intestinal T2 N1
17 Female 72 Intestinal T2 N1 49 Female 65 Intestinal T2 N1
18 Male 73 Intestinal T2 N2 50 Male 82 Intestinal T1 N0
19 Male 71 Intestinal T3 N2 51 Female 74 Mixed T1 N0
20 Female 67 Intestinal T2 N0 52 Male 72 Diffuse T3 N2
21 Male 67 Diffuse T3 N1 53 Female 60 Diffuse T3 N0
22 Female 64 Intestinal T3 N2 54 Male 47 Diffuse T2 N0
23 Female 72 Diffuse T3 N2 55 Female 74 Diffuse T2 N0
24 Male 74 Intestinal T2 N1 56 Male 65 Mixed T2 N2
25 Male 58 Intestinal T3 N3 57 Female 49 Intestinal T1 N0
26 Male 71 Intestinal T1 N0 58 Male 74 Intestinal T1 N0
27 Female 68 Mixed T3 N1 59 Male 58 Intestinal T1 N0
28 Male 74 Intestinal T2 N0 60 Male 53 Diffuse T2 N0
29 Male 57 Mixed T3 N1 61 Male 61 Diffuse T2 N1
30 Male 69 Diffuse T3 N1 62 Male 69 Diffuse T2 N1
31 Male 67 Intestinal T2 N0 63 Male 56 Intestinal T2 N0
32 Female 71 Intestinal T2 N1
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Fuse quality flag was below one or the confidence value
was below 0.1, spots were excluded from further analysis.
The log2 tumor to normal fluorescence ratio was calculated
for each spot and normalized against the mode of the ratios
of all autosomes. The package CGH call was used for data
segmentation and defining copy-number gains and losses of
each clone in the array CGH profile [29].
Multiplex ligation-dependent probe amplification
MLPA was performed, as previously described, [24] using
two different probe mixes. One probemix contained 38
probes representing 31 different genes on chromosome 20
and 10 control probes located on chromosomes 2, 3, 4, 5,
12, and 16. The second probemix contained 11 probes on
chromosome 8, 12 probes on chromosome 13, 16 probes on
chromosome 20 representing 14 different genes, and
8 control probes located on chromosomes 2, 4, 12, and
16. Some genes on chromosome 20 are present in both
probe mixes, leaving 35 different genes on chromosome 20
by combining these two probe mixes. DNA of the cell line
HT29, showing a gain on chromosomes 8, 13, and 20, was
used as positive control. A human pool of DNA isolated
from blood of 36 healthy individuals and a pool of DNA
isolated of 30 normal gastric and colon mucosa, spleen,
liver, and kidney tissue samples (FFPE), were used as
normal controls.
Of each sample, approximately 100 ng of DNA in a
volume of 5 µl was denaturated at 98°C for 5 min. A mixture
of 1.5-µl salsa probes (1–4 fmol of each short synthetic probe
oligonucleotide and each phage M13-derived long probe
oligonucleotide in TE (10 mM Tris-HCl, pH 8.2, 1 mM
ethylenediamine tetraacetic acid (EDTA))) and 1.5µl of
MLPA buffer (1.5 M KCl, 300 mM Tris-HCl, pH 8.5, 1 mM
EDTA) was added. The mixture was heated for 1 min at 95°C
followed by 16 h of incubation at 60°C to allow the MLPA
hemipobes to hybridize. Next, 32µl of ligase-65 mixture
(dilution buffer containing 2.6 mMMgCl2, 5 mM Tris-HCl,
pH 8.5, 0.013% non-ionic detergents, 0.2 mM of nicotin-
amide adenine dinucleotide (NAD), and 1 U of ligase-65
enzyme) was added to each sample for ligation of
hybridized hemiprobes during a 10–15 min of incubation
at 54°C, followed by a 5 min of incubation at 98°C to
inactivate the ligase.
Polymerase chain reaction (PCR) was performed with 10µl
of polymerase mixture containing the PCR primers (10 pmol),
dNTPs (2.5 nmol), and 2.5 U Taq polymerase (promega), 4µl
of PCR buffer (2.6 mM MgCl2, 5 mM Tris-HCl, pH 8.5,
0.013% non-ionic detergents, 0.2 mM NAD), 26µl of water
and 10µl of MLPA ligation reaction.
Fig. 1 Heatmap of DNA copy
number ratios of 11 genes on
chromosome 8, 12 genes on
chromosome 13, and 35 genes
on chromosome 20. The col-
umns represent different gastric
adenocarcinomas, and the rows
represent the different genes.
Darker squares indicate higher
DNA copy number ratios
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Multiplex ligation-dependent probe amplification data
analysis
Analysis of the MLPA PCR products for each gene was
performed on an ABI 3100 capillary sequencer (Applied
Biosystems, Warrington, UK) in a mixture of 8.5µl of
deionized formamide (Applied Biosystems, Warrington,
UK), 1µl of PCR product and 0.5µl marker including a
ROX-labeled internal size standard (ROX-500 Genescan;
Applied Biosystems, Warrington, UK). Data analysis was
performed using the MLPAnalyzer version 8.0 (http://www.
mlpa.com/coffalyser/) [30]. For each tumor, peak heights
for every probe were derived from the ABI output and
median peak heights of at least two different ligation
reactions and three different PCR reactions were calculated.
For each sample, tumor to normal DNA copy-number ratios
was calculated per probe by dividing the median peak
heights in the tumor tissue by the median peak heights in
the reference DNA. All ratios were normalized by setting
the median of the tumor to reference DNA copy-number
ratios of the control genes in the probe mixture to 1.0.
When multiple probes were present for one gene, the mean
value of the probes was calculated and used for further
analysis. Tumor to normal ratios below 0.7 and above 1.3
was considered as a loss or gain, respectively. TMEV
software 3.1 (http://www.tigr.org/) was used to present
descriptive data.
Statistical analysis
Box and scatter plots were used to present descriptive statistics.
Chi-square test was used to evaluate associations of DNA
copy-number gain of chromosomes 8q, 13q, and 20q with
clinicopathological variables. t Test was used to evaluate
differences in DNA copy-number aberrations and age of the
patients. Mann-Whitney U test and Kruskal-Wallis H test were
used to evaluate differences in DNA copy-number changes of
each gene between lymph node status and histological tumor
type according to the Laurén classification [31], respectively.
Correlation coefficients between the log2 ratios for the array
CGH and MLPA analysis were obtained by Spearman
correlation (SPSS 12.0.1 for Windows; SPSS Inc. Chicago,
IL, USA). A threshold of 0.05 for significance was used.
Results
Array CGH analysis and correlation with lymph node status
and histological type
Of the 63 gastric adenocarcinomas analyzed by array CGH,
49 (77.8%) showed gains on chromosome 8, 25 (39.7%)
Fig. 3 Box plot of DNA copy number ratios of the gene ZNF217
between intestinal-, diffuse-, and mixed-type gastric adenocarcinomas.
DNA copy number ratios of ZNF217 are significantly different between
gastric adenocarcinomas of different histological types (p=0.02)
Fig. 2 Box plot of DNA copy number ratios of the gene TNFRFS6B
between lymph node-negative and lymph node-positive gastric adeno-
carcinomas. Lymph node-positive gastric adenocarcinomas have
significantly higher DNA copy number ratios of TNFRFS6B compared
with lymph node-negative gastric adenocarcinomas (p=0.02). The
central box covers the middle 50% of the data values between the
upper and lower quartiles. The line across the box indicates the median.
The whiskers extend from the box to the minimum and maximum
values with the exception of outliers, which are marked by circles
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showed gains on chromosome 13, and 49 (77.8%) showed
gains on chromosome 20. Concurrent gains of chromo-
somes 8 and 13, 8 and 20, and 13 and 20 were observed in
four (6.3%), 24 (38.1%), and three (4.8%) of the gastric
adenocarinomas, respectively. Concurrent gains of chromo-
somes 8, 13, and 20 were observed in 17 (27%) gastric
adenocarcinomas. Gain of chromosome 20q was signifi-
cantly correlated with lymph node status (p=0.05) and
histological type of the tumor (p=0.02), being more common
in lymph node-positive gastric cancers (85%) than in lymph
node-negative gastric cancers (64%) and more common in
intestinal-type (87%) and mixed-type (88%) gastric cancers
than in diffuse-type (53%) gastric cancers. No significant
(NS) correlation was found between 20q gain and age and
gender of the patients and tumor size. No correlation of 8q
gain or 13q gain with clinicopathological variables was
found. An overview of the frequencies of copy-number gains
on chromosomes 8q, 13q, and 20q detected by array CGH
analysis is given in Table 1. An overview of patient and
tumor characteristics is given in Table 2.
Multiplex ligation-dependent probe amplification analysis
of DNA copy-number aberrations and correlation
with lymph node status and histological type
All 63 gastric adenocarcinomas analyzed by array CGHwere
analyzed by MLPA. An overview of the DNA copy-number
ratios of all individual genes on chromosomes 8, 13, and 20
in all tumor samples is presented as a heatmap in Fig. 1.
Gains of genes on chromosome 8q were observed in
9.5%–73.0% of the gastric adenocarcinomas, with the
highest frequencies of gains observed in c-myc (73.0%).
Gains of genes on chromosome 13q were detected in
11.1%–28.6%, with the highest frequencies of gains
observed in FOXO1A and ATP7B (both 28.6%). Frequent
DNA copy-number gains of multiple genes on chromosome
20q were observed. Gain of TOP1, PTPN1, CYP24A1, and
GATA5 was observed in more than 60% of the gastric
adenocarcinomas, and gain of BCL2L1, MYBL2, STX16,
and GNAS was observed in more than 70% of the gastric
adenocarcinomas. When correlating gene-specific copy-
number status to lymph node status, EIF3S6 (p=0.04),
located on chromosome 8q22 and TNFRSF6B (p=0.02),
located on chromosome 20q13.3, were significantly differ-
ent between lymph node-positive and lymph node-negative
gastric adenocarcinomas. Although Mann-Whitney U test
yielded a significant difference in copy-number of the gene
EIF3S6 between lymph node-positive and lymph node-
negative gastric adenocarcinomas, mean copy-number ratio
of both carcinoma groups were within the normal copy-
number range (DNA copy-number ratio between 0.7 and
1.3). Lymph node-positive gastric adenocarcinomas showed
gain (DNA copy-number ratio >1.3) of TNFRSF6B while
lymph node negative gastric adenocarcinomas showed
normal copy-number ratios of this gene (Fig. 2). When
correlating gene-specific copy-number ratio to histological
tumor type, Kruskall-Wallis H test yielded five significant
genes. Mean copy-number ratios of FBXO25 (p=0.01),
located on 8p23.3, RASL11A (p=0.03), located on 13q12.2
and CDX2 (p=0.03), located on 13q12, were within the
normal copy-number range for all three tumor types. Mean
Fig. 4 Scatter plots of the log2 ratios of the BAC clone and MLPA
probe of the TNFRFS6B (a) and ZNF217 (b) genes. A significant
correlation was detected for both genes (p<0.001, r=0.57 and r=0.51,
respectively)
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copy-number ratio of ZNF217 (p=0.02), located on
20q13.2, showed gain in intestinal and mixed histological
gastric cancer types versus normal in the diffuse histolog-
ical types (Fig. 3). STX16 (p=0.03), located on 20q13.32,
showed mean copy-number gain in all three tumor types,
but higher mean copy-number ratios in the intestinal and
mixed types of gastric carcinomas compared with diffuse-
type gastric carcinomas (1.90, 2.03, and 1.47, respectively).
A detailed overview of the frequencies of gains per gene
and mean copy-number ratio per tumor group, i.e., lymph
node-positive versus lymph node-negative gastric adeno-
carcinomas and intestinal- versus diffuse- versus mixed-
type gastric carcinomas are given in Table 3.
Correlation of copy-number status of MLPA and array
CGH
The BAC clones RP4-583P15 and RP4-724E16 comprised
the location of the TNFRSF6B and ZNF217 genes,
respectively. To evaluate the correlation between the array
CGH and MLPA data, the MLPA DNA copy-number ratios
were transformed to a log2 scale. Spearman correlation
yielded a significant correlation between array CGH and
MLPA data for both TNFRSF6B (r=0.57, p<0.001;
Fig. 4a) and ZNF217 (r=0.51, p<0.001; Fig. 4b).
Discussion
Gastric cancer is a common disease with a poor prognosis
[1]. Chromosomal instability is a major mechanism of
genetic instability in gastric cancers which has been widely
studied by array CGH analysis [2, 32]. Frequent copy-
number gains of chromosomes 8q, 13q, and 20q have been
detected in gastric adenocarcinomas by this technique [3–
10]. In this study, we report a detailed analysis of DNA
copy-number changes of genes located on chromosomes 8,
13, and 20 in gastric adenocarcinomas aiming to correlate
gene-specific alterations to clinicopathological data.
In the present study of 63 gastric adenocarcinomas
studied by array CGH, nearly 80% of the cancers showed
gain of chromosomes 8q and 20q. These frequencies of
gains are consistent with previous studies where gains of
chromosomes 8q and 20q were reported in 40–80% and
50–80% of gastric cancers, respectively [4, 10, 13, 14, 17,
33]. Both gains and losses of chromosome 13q have been
detected in gastric cancers. Losses of chromosome 13q
have been described in up to 30% of gastric cancers and
gains of 13q have been described in up to 40% of gastric
cancers [4, 10, 13–15, 17, 33], which is consistent with the
findings of the present study.
When analyzing DNA copy-number gain at the gene
level, mean copy-number ratio of two genes, EIF3S6E
(8q22) and TNFRSF6B (20q12.3), correlated significantly
with lymph node status. Mean copy-number ratios of
EIF3S6E were within the normal range for both lymph
node-positive and lymph node-negative gastric cancers,
corresponding to the array CGH results in this study. Mean
copy-number ratio of TNFRSF6B was significantly higher
in lymph node-positive compared with lymph node-
negative gastric cancers and was within the range of DNA
copy-number gain and normal, respectively. Although 20q
gain CGH data correlated with lymph node metastasis, of
the 20q genes tested, only DNA copy-number gain of
TNFRSF6B was significantly correlated with lymph node
metastasis. TNFRSF6B is a member of the tumor necrosis
factor receptor superfamily and is also known as decoy
receptor 3 (DrR3). TNFRSF6B binds to FasL and inhibits
FasL-induced apoptosis [34]. Overexpression of this gene has
been observed in multiple cancer types, including cancers of
the gastrointestinal tract. Interestingly, gastric cancers with
pN2 and pN3 diseases have been shown to have significantly
higher TNFRSF6B expression compared with gastric cancers
with pN0 and pN1 diseases. Serum levels of TNFRSF6B
were correlated with TNM stage in gastric cancers [35, 36].
We found TNFRSF6B DNA copy-number ratios on average
to be gained in gastric cancers metastasized to the lymph
nodes (pN1–3) compared with on average normal DNA
copy-number ratios of TNFRSF6B in non-metastasized
gastric cancers (pN0). Although previous studies have
reported overexpression of TNFRSF6B without gene ampli-
fication [37], results of the present study indicate that DNA
copy-number status of TNFRSF6B could be a valuable
marker for identifying lymph node-positive gastric cancers.
DNA copy-number status of five genes, FBXO25
(8p23.3), RASL11A (13q12.2), CDX2 (13q12), ZNF217
(20q13.2), and STX16 (20q13.32), correlated significantly
with histological tumor type, i.e., intestinal-, diffuse-, or
mixed-type gastric cancer. Mean DNA copy-number ratios
of FBXO25, RASL11A, and CDX2, however, were within
the normal copy-number range for all three histological
types, in consistence with the array CGH data of this study.
The biological meaning of this difference, therefore, is not
immediately clear, but could, e.g., relate to only a
subpopulation of tumor cells being affected.
STX16 showed significantly higher mean copy-number
ratios in intestinal- and mixed-type compared with diffuse-
type gastric cancers; however, DNA copy-number gain was
observed in all three tumor groups. STX16 encodes a syntaxin
protein which plays a role in intracellular trafficking [38], but
its role in cancer still has to be elucidated.
ZNF217 encodes a transcription factor which was shown
to be involved in immortalization of breast cancer cells
when overexpressed [39]. High-level amplifications of
ZNF217 have been previously described in approximately
10% of gastric cancers [9, 10, 40]. In the study of Weiss et
Virchows Arch (2009) 455:213–223 221
al. on three tumors, all of the intestinal-type, out of 27
gastric adenocarcinomas, showed an amplification on
20q13. Fluorescence in situ hybridization (FISH) analysis
was performed on these three tumors, confirming the copy-
number increase at this locus [9]. Results from the present
study suggest that DNA copy-number gain of ZNF217
plays a more important role in intestinal- and mixed-type
compared with diffuse-type gastric cancers, since gains of
mean copy-number ratios are observed in intestinal- and
mixed-type gastric cancers and normal mean copy-number
ratio in diffuse-type gastric cancers.
In summary, we present a detailed DNA copy-number
analysis of a panel of genes located on chromosomes 8, 13, and
20 in gastric adenocarcinomas. We found that DNA copy-
number gain of ZNF217 plays a role mainly in intestinal- and
mixed-type but not in diffuse-type gastric adenocarcinomas.
In addition, we showed that DNA copy-number gain of
TNFRSF6B is significantly correlated to gastric cancers with
lymph node metastasis, indicating a potential role for this
gene as a biomarker for identifying patients at high risk of
lymph node metastasis, who might, therefore, benefit from
extended lymph node resection or neoadjuvant chemotherapy
to improve gastric cancer outcome.
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